IP Library Patent Application 18132253
Patent Application
App. No. 18/132,253

METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/132,253
Abstract

The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-05 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.

Claims (9)

1 . (canceled)

2 . A method of treating geographic atrophy secondary to age-related macular degeneration in a human subject, the method comprising administering by intravitreal injection, to said subject, 2 mg/eye of a pegylated aptamer;

wherein the aptamer comprises the sequence fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGfUfCfU mGmAmGfUfUfUAfCfCfUmGfCmG-3T (SEQ ID NO: 26),

wherein fC and fU=2′-fluoro nucleotides, mG and mA=2′-OMe nucleotides, all other nucleotides are 2′-OH, and 3T indicates an inverted deoxythymidine, or a salt thereof;

wherein the pegylated moiety has the following structure:

and

wherein the pegylated aptamer is administered to the subject monthly.

3 . The method of claim 2 , wherein the pegylated aptamer is administered in an aqueous solution further comprising one or more pH buffering agents and at least one tonicity adjuster.

4 . The method of claim 3 , where the one or more pH buffering agents comprise dibasic sodium phosphate heptahydrate and monobasic sodium phosphate monohydrate, and the at least one tonicity adjuster comprises sodium chloride.

Assignments (3)
MERGER Recorded Jun 26, 2024
From: IVERIC BIO, INC.
To: ASTELLAS US LLC
Reel/Frame 067851/0643 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2024
From: PATEL, SAMIR; EVERETT, RICHARD; BROOKS, DOUGLAS; TIAN, SHANE XINXIN
To: OPHTHOTECH CORPORATION
Reel/Frame 067230/0205 →
CHANGE OF NAME Recorded Apr 25, 2024
From: OPHTHOTECH CORPORATION
To: IVERIC BIO, INC.
Reel/Frame 067239/0430 →